Neuroscience and Behavioral Physiology

, Volume 49, Issue 3, pp 352–356 | Cite as

Systemic Inflammatory Markers in Age-Associated Cognitive Impairment and Alzheimer’s Disease

  • T. P. KliushnikEmail author
  • L. V. Androsova
  • N. M. Mikhaylova
  • I. V. Kolykhalov
  • S. A. Zozulya
  • A. M. Dupin

Objectives. A set of immune markers reflecting different branches of multicomponent inflammatory reactions were assessed in mild cognitive impairment syndrome of the amnestic type (aMCI) in comparison with patients with Alzheimer’s disease (AD). A total of 67 patients aged 72 [63; 77] years with aMCI and 91 patients aged 74 [68; 79] years with AD were investigated. aMCI was diagnosed in accordance with the Petersen et al. (1999) criteria and the Dubois et al. (2014) criteria. Diagnoses of AD were made on the basis of ICD-10 and NINCDS-ADRDA criteria. The severity of dementia was determined on the basis of clinical signs using the CDR (Clinical Dementia Rating) scales and total Mini Mental State Examination (MMSE) scores. The control group consisted of 38 subjects with age and gender comparable to those of the study groups. Immunobiochemical investigations were performed using plasma. Leukocyte elastase (LE) and α1-proteinase inhibitor (α1-PI) activities were estimated spectrophotometrically and interleukin-6 (IL-6) and C-reactive protein (CRP) levels were measured using an immunoenzyme method. Results. A significant decrease in LE activity was seen in the AD group (p < 0.0001), along with increases in the activity/ levels of acute-phase proteins (α1-PI and CRP) and IL-6 (p < 0.0001, p < 0.05, and p < 0.01, respectively). Clinical-biochemical correlations were found between CDR, MMSE, and LE activity (r = –0.38, r = 0.31, p < 0.05), i.e., the more severe the cognitive decline in the state of dementia, as reflected in the MMSE and clinical symptoms, the lower the level of LE activity. Among patients with aMCI, there were significant increases in the activity/levels of α1-PI and IL-6 (p < 0.0001, p < 0.01), while only 30% of patients showed the spectrum of inflammatory markers typical of patients with AD. Conclusions. The results of this comparative analysis of the spectrum of inflammatory markers in patients with aMCI and AD suggest that about a third of aMCI patients constitute a group at extremely high risk of developing AD and require follow-up with regular assessment of the state of cognitive functions and, perhaps, of preventive therapy.


Alzheimer’s disease mild cognitive impairment syndrome inflammatory markers leukocyte elastase interleukin-6 acute-phase proteins 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Y. J. Lee, S. B. Han, S. Y. Nam, et al., “Inflammation and Alzheimer’s disease,” Arch. Pharm. Res., 33, No. 10, 1539–1556 (2010), Scholar
  2. 2.
    L. Tay, W. S. Lim, M. Chan, et al., “The independent role of inflammation in physical frailty among older adults with mild cognitive impairment and mild-to-moderate Alzheimer’s disease,” J. Nutr. Health Aging, 20, No. 3, 288–299 (2016), Scholar
  3. 3.
    E. Dursun, D. Gezen-Ak, H. Hanağası, et al., “The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer’s disease, mild cognitive impairment or Parkinson’s disease,” J. Neuroimmunol., 283, 50–57 (2015), Scholar
  4. 4.
    K. Yaffe, A. Kanaya, K. Lindquist, et al., “The metabolic syndrome, inflammation, and risk of cognitive decline,” JAMA, 292, No. 18, 2237–2242 (2004).CrossRefGoogle Scholar
  5. 5.
    D. Kempuraj, R. Thangavel, P. A. Natteru, et al., “Neuroinflammation Induces Neurodegeneration,” J. Neurol. Neurosurg. Spine, 1, No. 1, 1003 (2016).Google Scholar
  6. 6.
    S. I. Gavrilova, “Approaches to the preventive therapy of Alzheimer’s disease: challenges and possibilities,” Psikhiatriya, 61, No. 01, 5–12 (2014).Google Scholar
  7. 7.
    A. Gabelle, I. Jaussent, C. Hirtz, et al., “Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process,” Neurobiol. Aging, 53, 59–66 (2017), Scholar
  8. 8.
    O. H. Al-Jiffri, F. M. Al-Sharif, E. H. Al-Jiffri, and V. N. Uversky, “Intrinsic disorder in biomarkers of insulin resistance, hypoadiponectinemia, and endothelial dysfunction among the type 2 diabetic patients,” Intrinsically Disord. Proteins, 4, No. 1, e1171278 (2016), Scholar
  9. 9.
    S. Piirainen, A. Youssef, C. Song, et al., “Psychosocial stress on neuroinflammation and cognitive dysfunctions in Alzheimer’s disease: the emerging role for microglia?” Neurosci. Biobehav. Rev., 77, 148–164 (2017), Scholar
  10. 10.
    B. S. Ashok, T. A. Ajith, and S. Sivanesan, “Hypoxia-inducible factors as neuroprotective agent in Alzheimer’s disease,” Clin. Exp. Pharmacol. Physiol., 44, No. 3, 327–334 (2017), Scholar
  11. 11.
    E. M. Ribe and S. Lovestone, “Insulin signalling in Alzheimer’s disease and diabetes: from epidemiology to molecular links,” J. Intern. Med., 280, No. 5, 430–442 (2016), Scholar
  12. 12.
    M. Bozluolcay, G. Andican, S. Fırtına, et al., “Inflammatory hypothesis as a link between Alzheimer’s disease and diabetes mellitus,” Geriatr. Gerontol. Int., 16, No. 10, 1161–1166 (2016), Scholar
  13. 13.
    M. A. Pal’tsev (ed.), Lectures in General Pathological Anatomy: Textbook, Russkii Vrach, Moscow (2003).Google Scholar
  14. 14.
    V. R. Varma, S. Varma, Y. An, et al., “Alpha-2 macroglobulin in Alzheimer’s disease: a marker of neuronal injury through the RCAN1 pathway,” Mol. Psychiatry, 22, No. 1, 13–23 (2017), Scholar
  15. 15.
    M. T. Schram, S. M. Euser, A. J. de Craen, et al., “Systemic markers of inflammation and cognitive decline in old age,” J. Am. Geriatr. Soc., 55, No. 5, 708–716 (2007), Scholar
  16. 16.
    P. Komulainen, T. A. Lakka, M. Kivipelto, et al., “Serum high sensitivity C-reactive protein and cognitive function in elderly women,” Age Ageing, 36, No. 4, 443–448 (2007).CrossRefGoogle Scholar
  17. 17.
    L. V. Androsova, N. M. Mikhaylova, S. A. Zozulya, et al., “Inflammatory makers in Alzheimer’s disease and vascular dementia,” Zh. Nevrol. Psikhiat., 113, No. 2, 49–53 (2013).Google Scholar
  18. 18.
    T. P. Kliushnik, L. V. Androsova, N. M. Mikhaylova, et al., “Potential markers for Alzheimer’s disease associated with inflammation,” Psikhiatriya, 61, No. 1, 26–32 (2014).Google Scholar
  19. 19.
    L. Androsova, N. Mikhaylova, S. Zozulya, et al., “A comparative study of innate immunity markers in Alzheimer’s disease, Mixed dementia and Vascular dementia,” Int. J. Clin. Neurosci. Ment. Health, 3, Suppl. 1, 03 (2016), (Suppl.1).S03.
  20. 20.
    R. C. Petersen, G. E. Smith, S. C. Waring, et al., “Mild cognitive impairment: clinical characterization and outcome,” Arch. Neurol., 56, No. 3, 303–308 (1999).CrossRefGoogle Scholar
  21. 21.
    B. Dubois and M. L. Albert, “Amnestic MCI or prodromal Alzheimer’s disease,” Lancet Neurol., 3, 246–248 (2004).CrossRefGoogle Scholar
  22. 22.
    B. Dubois, H. H. Feldman, C. Jacova, et al., “Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria,” Lancet Neurol., 13, No. 6, 614-629 (2014), Scholar
  23. 23.
    G. McKhann, D. Drachman, M. Folstein, et al., “Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease,” Neurology, 34, No. 7, 939–944 (1984).CrossRefGoogle Scholar
  24. 24.
    C. P. Hughes, L. Berg, W. L. Danziger, et al., “A new clinical scale for the staging of dementia,” Br. J. Psychiatr., 140, No. 3, 566–572 (1982).CrossRefGoogle Scholar
  25. 25.
    M. F. Folstein, S. F. Folstein, and P. R. McHugh, “Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician,” J. Psychiatr. Res., 12, 189–198 (1975).CrossRefGoogle Scholar
  26. 26.
    V. L. Dotsenko, E. A. Neshkova, and G. A. Yarovaya, “Detection of human leukocyte elastase from the complex with plasma α1-proteinase inhibitor on the basis of its enzyme activity with a synthetic substrate,” Vopr. Med. Khim., 40, No. 3, 20–25 (1994).Google Scholar
  27. 27.
    V. F. Nartikova and T. S. Paskhina, “A unified method for assay of human serum (plasma) α1-antitrypsin and α2-macroglobulin activity,” Vopr. Med. Khimii, 25, No. 4, 494–499 (1979).Google Scholar
  28. 28.
    S. I. Gavrilova, Ya. B. Fedorova, I. F. Roshchina, and G. I. Korovaitseva, “Prognosis of mild cognitive impairment syndrome on the basis of data from a two-year clinical follow-up study,” Zh. Nevrol. Psikhiat., 107, No. 1, 1–11 (2007).Google Scholar
  29. 29.
    A. Le Page, J. Lamoureux, K. Bourgade, et al., “Immune signatures of Alzheimer’s disease: profiles of neutrophils. (HUM 1P.301),” J. Immunol., 194, Suppl. 1, 52.26 (2015).Google Scholar
  30. 30.
    S. H. Baik, M. Y. Cha, Y. M. Hyun, et al., “Migration of neutrophils targeting amyloid plaques in Alzheimer’s disease mouse model,” Neurobiol. Aging, 35, No. 6, 1286–1292 (2014), Scholar
  31. 31.
    E. Zenaro, E. Pietronigro, V. Della Bianca, et al., “Neutrophils promote Alzheimer’s disease -like pathology and cognitive decline via LFA-1 integrin,” Nat. Med., 21, No. 8, 880–886 (2015), Scholar
  32. 32.
    T. G. Fong, D. Davis, M. E. Growdon, et al., “The interface between delirium and dementia in elderly adults,” Lancet Neurol., 14, No. 8, 823–832 (2015), Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • T. P. Kliushnik
    • 1
    Email author
  • L. V. Androsova
    • 1
  • N. M. Mikhaylova
    • 1
  • I. V. Kolykhalov
    • 1
  • S. A. Zozulya
    • 1
  • A. M. Dupin
    • 1
  1. 1.Mental Health Research CenterMoscowRussia

Personalised recommendations